New study aims to outsmart malaria by blocking it early in life
NCT ID NCT04978272
First seen Apr 26, 2026 · Last updated Apr 26, 2026
Summary
This study tests whether giving young children monthly malaria prevention medicine (dihydroartemisinin-piperaquine) from 8 weeks old up to 1 or 2 years of age can help their bodies build stronger immunity against malaria. About 924 children in Uganda will be followed until age 4 to see if those who received early prevention have fewer malaria episodes later. The goal is to find a better way to protect children in malaria-prone areas.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IDRC - Tororo Research Clinic
Tororo, Uganda
Conditions
Explore the condition pages connected to this study.